Quanti OBR: A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)
Study Details
Study Description
Brief Summary
Researchers are looking for a better way to help people with any known or suspected problems (except brain or spinal cord-related problems) scheduled for a "contrast-enhanced" Magnetic Resonance Imaging (MRI).
MRI is used by doctors to create detailed images of the inside of the body to identify health problems. Sometimes doctors need to inject contrast agent into a patient's vein to perform a "contrast-enhanced" MRI (CE-MRI). Such CE-MRI may help identify certain health problems or improve the evaluation.
The contrast agents commonly used in MRI are gadolinium-based contrast agents (GBCAs). GBCAs contain a "rare earth" element called gadolinium (Gd). Gadoquatrane is a new contrast agent under development with a lower amount of Gd needed per CE-MRI.
The main purpose of this study is to learn whether CE-MRI scans with gadoquatrane work better than MRI scans without the use of a contrast agent (GBCA). The researchers will compare the ability to detect known or suspected problems (except brain or spinal cord-related problems) with gadoquatrane-MRI scans to plain-MRI scans without the use of a contrast agent.
The participants will undergo 2 MRI scans, one with gadoquatrane and one with currently used GBCA. Both contrast agents will be injected into the vein.
Each participant will be in the study for between 6 and 42 days with up to 7 doctor visits.
At the start or during the study, the doctors and their study team will:
-
take blood and urine samples
-
do physical examinations
-
check blood pressure and heart rate
-
review the MRI scans obtained in the study and decide on the diagnosis
-
ask the participants questions about how they are feeling and what adverse events they are having.
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Gadoquatrane - Approved Macrocyclic GBCA Participants will receive one intravenous injection of gadoquatrane during MRI in Period 1, followed by one intravenous injection of any approved macrocyclic GBCA during MRI in Period 2. |
Drug: Gadoquatrane (BAY1747846)
0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
Drug: Gadobutrol
Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
Drug: Gadoterate meglumine
Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
Other Names:
Drug: Gadoteridol
Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
|
Experimental: Approved Macrocyclic GBCA - Gadoquatrane Participants will receive one intravenous injection of any approved macrocyclic GBCA during MRI in Period 1, followed by one intravenous injection of gadoquatrane during MRI in Period 2. |
Drug: Gadoquatrane (BAY1747846)
0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
Drug: Gadobutrol
Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
Drug: Gadoterate meglumine
Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
Other Names:
Drug: Gadoteridol
Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
|
Outcome Measures
Primary Outcome Measures
- Visualization parameter contrast Enhancement assessed by separate blinded evaluation of unenhanced and combined pre- and post-gadoquatrane MRI, by a BICR [1 day procedure]
Contrast Enhancement will be assessed on a 4-point scale (1/No: not enhanced, 2/Moderate: weakly enhanced, 3/Good: clearly enhanced, 4/Excellent: clearly and brightly enhanced). BICR = blinded independent central read / blinded independent central readers; MRI = magnetic resonance imaging
- Visualization parameter delineation assessed by separate blinded evaluation of unenhanced and combined pre- and post-gadoquatrane MRI, by a BICR [1 day procedure]
Delineation will be assessed on a 4-point scale (1/No: no or unclear delineation, 2/Moderate: some aspects of delineation, 3/Good: almost clear but not complete, 4/Excellent: clear and complete delineation). BICR = blinded independent central read / blinded independent central readers; MRI = magnetic resonance imaging
- Visualization parameter morphology assessed by separate blinded evaluation of unenhanced and combined pre- and post-gadoquatrane MRI, by a BICR [1 day procedure]
Morphology will be assessed on a 3-point scale (1/Poor: no or poorly evaluable, 2/Moderate: partially evaluable, 3/Good: sufficiently evaluable). BICR = blinded independent central read / blinded independent central readers; MRI = magnetic resonance imaging
Secondary Outcome Measures
- Visualization parameter contrast assessed by separate blinded evaluation of combined pre- and post-gadoquatrane MRI and combined pre- and post-comparator MRI with macrocyclic GBCAs, by a BICR [1 day procedure]
Contrast Enhancement will be assessed on a 4-point scale (1/No: not enhanced, 2/Moderate: weakly enhanced, 3/Good: clearly enhanced, 4/Excellent: clearly and brightly enhanced). BICR = blinded independent central read / blinded independent central readers; MRI = magnetic resonance imaging; GBCAs = gadolinium-based contrast agents
- Visualization parameter delineation assessed by separate blinded evaluation of combined pre- and post-gadoquatrane MRI and combined pre- and post-comparator MRI with macrocyclic GBCAs, by a BICR [1 day procedure]
Delineation will be assessed on a 4-point scale (1/No: no or unclear delineation, 2/Moderate: some aspects of delineation, 3/Good: almost clear but not complete, 4/Excellent: clear and complete delineation). BICR = blinded independent central read / blinded independent central readers; MRI = magnetic resonance imaging; GBCAs = gadolinium-based contrast agents
- Visualization parameter morphology assessed by separate blinded evaluation of combined pre- and post-gadoquatrane MRI and combined pre- and post-comparator MRI with macrocyclic GBCAs, by a BICR [1 day procedure]
Morphology will be assessed on a 3-point scale (1/Poor: no or poorly evaluable, 2/Moderate: partially evaluable, 3/Good: sufficiently evaluable). BICR = blinded independent central read / blinded independent central readers; MRI = magnetic resonance imaging; GBCAs = gadolinium-based contrast agents
- Sensitivity for the detection of lesions of combined pre- and post-gadoquatrane MRI and combined pre- and post-comparator MRI with macrocyclic GBCAs, by a BICR [1 day procedure]
BICR = blinded independent central read / blinded independent central readers; MRI = magnetic resonance imaging; GBCAs = gadolinium-based contrast agents
- Specificity for the detection of lesions of combined pre- and post-gadoquatrane MRI and combined pre- and post-comparator MRI with macrocyclic GBCAs, by a BICR [1 day procedure]
BICR = blinded independent central read / blinded independent central readers; MRI = magnetic resonance imaging; GBCAs = gadolinium-based contrast agents
- The overall diagnostic clinical value of combined pre- and post-gadoquatrane MRI and combined pre- and post-comparator MRI with macrocyclic GBCAs [1 day procedure]
The overall diagnostic clinical value is composed of 2 elements and based on: i.the evaluation of diagnostic descriptive imaging features adapted from radiologic reporting standards (detection/exclusion of enhancing pathology; location, extent, and pattern of enhancement) on a 5-point scale (1- no diagnostic clinical value from contrast enhancement, 2- poor diagnostic clinical value from contrast enhancement, 3- moderate diagnostic clinical value from contrast enhancement, 4- good diagnostic clinical value from contrast enhancement, 5- excellent diagnostic clinical value from contrast enhancement), by the BICR and the Investigator; ii. the evaluation of patient management based on the diagnostic reporting recommendations (i.e., likely diagnosis), by the Investigator. BICR = blinded independent central read / blinded independent central readers; MRI = magnetic resonance imaging
- Sensitivity for the detection of malignant lesions of combined pre- and post-gadoquatrane MRI and combined pre- and post-comparator MRI with macrocyclic GBCAs assessed by BICR and the investigator [1 day procedure]
BICR = blinded independent central read / blinded independent central readers; MRI = magnetic resonance imaging; GBCAs = gadolinium-based contrast agents
- Specificity for the detection of malignant lesions of combined pre- and post-gadoquatrane MRI and combined pre- and post-comparator MRI with macrocyclic GBCAs assessed by BICR and the investigator [1 day procedure]
BICR = blinded independent central read / blinded independent central readers; MRI = magnetic resonance imaging; GBCAs = gadolinium-based contrast agents
- Diagnoses from combined pre- and post- gadoquatrane MRI and combined pre- and post-comparator MRI with macrocyclic GBCAs by the Investigator [1 day procedure]
BICR = blinded independent central read / blinded independent central readers; MRI = magnetic resonance imaging; GBCAs = gadolinium-based contrast agents
- Confidence in diagnosis combined pre- and post- gadoquatrane MRI and combined pre- and post-comparator MRI with macrocyclic GBCAs by BICR and by Investigator [1 day procedure]
The degree of confidence will be rated on a 4-point scale: 1 = Not confident, 2 = Somewhat confident, 3 = Confident, 4 = Very confident. BICR = blinded independent central read / blinded independent central readers; MRI = magnetic resonance imaging; GBCAs = gadolinium-based contrast agents
- Number of lesions seen on unenhanced MRI image set and combined pre- and post-gadoquatrane MRI and combined pre- and post-comparator MRI with macrocyclic GBCAs, by a BICR [1 day procedure]
BICR = blinded independent central read / blinded independent central readers; MRI = magnetic resonance imaging; GBCAs = gadolinium-based contrast agents
- Number of enhancing lesions seen on combined pre- and post- gadoquatrane MRI and combined pre- and post-comparator MRI with macrocyclic GBCAs, by a BICR [1 day procedure]
BICR = blinded independent central read / blinded independent central readers; MRI = magnetic resonance imaging; GBCAs = gadolinium-based contrast agents
- Number of participants with treatment emergent adverse events, including number of serious adverse events, after administration of gadoquatrane compared to macrocyclic GBCAs reported by the investigator [Within 24 ± 4 hours after administration of gadoquatrane or any approved macrocyclic GBCAs]
GBCAs = gadolinium-based contrast agents
- Number of participants with treatment emergent adverse events, including number of serious adverse events, per intensity after administration of gadoquatrane compared to macrocyclic GBCAs reported by the investigator [Within 24 ± 4 hours after administration of gadoquatrane or any approved macrocyclic GBCAs]
GBCAs = gadolinium-based contrast agents
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participant must be >= 18 years of age inclusive, at the time of signing the informed consent form
-
Participants with a clinical indication for a contrast-enhanced MRI (including magnetic resonance angiography [MRA]), with any approved standard of care macrocyclic GBCA with proven efficacy, safety and tolerability in clinical routine CE-MRI/MRA (gadobutrol, gadoterate meglumine/ gadoteric acid or gadoteridol) that is used at the site for the indication, with known or suspected pathology of any body region, e.g. head and neck (except central nervous system [CNS]), thorax (including e.g. breast, heart, chest wall), abdomen (including e.g. liver, kidney, pancreas), pelvis (including e.g. prostate, uterus, ovaries), extremities (including upper and lower.
-
Participants who can undergo study-related procedures, including 2 contrast-enhanced MRI examinations (one with gadoquatrane and one with a comparator macrocyclic GBCA), as per participant and Investigator's judgement
-
Contraceptive use by female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: Is a woman of nonchildbearing potential (WONCBP) OR Is a woman of childbearing potential (WOCBP) and using an acceptable contraceptive method during the study intervention period (at a minimum of 24 hours after the last dose of study intervention).
Exclusion Criteria:
-
Considered clinically unstable or has a concurrent/concomitant condition that may significantly alter image comparability between the 2 study MRIs or between study parameters (e.g. safety, pharmacokinetics [PK] parameters) or would not allow participation for the full planned study period, in the judgement of the investigator
-
Participants presenting with severe renal insufficiency, defined as an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m^2, derived from a serum creatinine sample obtained within 48 hours prior to the first contrast agent injection in the study
-
Participants with acute kidney injury (i.e., acute renal failure), regardless of eGFR
-
History of moderate to severe allergic-like reaction to any GBCA
-
Bronchial asthma considered unstable and/or requiring medical treatment
-
Receipt of any contrast agent < 72 h prior to the study MRIs or planned to receive any contrast agent during the trial until 24 h +/- 4 h after the second study MRI
-
Planned or expected interventional diagnostic or therapeutic procedure (e.g. biopsy or surgery in the region of interest) or change in treatment (e.g. start of chemotherapy or antiangiogenic therapy, significant change in corticosteroids dose) that may significantly alter image comparability between the 2 MRIs or other study parameters (i.e. safety/adverse events [AEs] [e.g. confounding AEs or safety events due to surgery or chemotherapy], PK parameters), from the first study MRI up to 24 h after the second study MRI
-
Has received any investigational product within 30 days, or within 5 times half-life of the investigational product, whatever is shorter, prior to or concurrent with this study
-
Contraindications to the administration of macrocyclic GBCAs (depending on local product label), or history of adverse reaction to gadoquatrane
-
Any contraindication to MRI examinations based on institution policy and investigator's clinical judgement (e.g. some metallic implants or active implants)
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University of Alabama at Birmingham | Birmingham | Alabama | United States | 35233 |
2 | Halo Diagnostics | Indian Wells | California | United States | 92210 |
3 | UC Irvine Medical Center | Orange | California | United States | 92868 |
4 | University of Connecticut Health Center | Farmington | Connecticut | United States | 06030 |
5 | Northwestern University | Chicago | Illinois | United States | 60611 |
6 | Boston Medical Center | Boston | Massachusetts | United States | 02118 |
7 | University of Missouri Hospital and Clinic - Neuroradiology | Columbia | Missouri | United States | 65212 |
8 | Duke University School of Medicine | Durham | North Carolina | United States | 27710 |
9 | Pennsylvania State University College of Medicine | Hershey | Pennsylvania | United States | 17033 |
10 | Houston Methodist Hospital | Houston | Texas | United States | 77030 |
11 | University of Wisconsin - Madison | Madison | Wisconsin | United States | 53792 |
12 | Fundacion Cientifica del Sur | Lornas De Zamora | Buenos Aires | Argentina | B1832BQS |
13 | Sanatorio Otamendi | Buenos Aires | Ciudad Auton. De Buenos Aires | Argentina | C1115AAB |
14 | Centro de Diagnóstico Dr. Enrique Rossi | Buenos Aires | Ciudad Auton. De Buenos Aires | Argentina | C1425BEE |
15 | Instituto Medico Especializado Alexander Fleming | Caba | Ciudad Auton. De Buenos Aires | Argentina | C1426 |
16 | Sanatorio Allende | Departamento de Investigación Clínica | Córdoba | Argentina | X5000JHQ | |
17 | Clínica Universitaria Reina Fabiola | Córdoba | Argentina | X5004FHP | |
18 | UMHAT Dr. Georgi Stranski | Pleven | Bulgaria | 5800 | |
19 | UMHAT Sveti Georgi | Plovdiv | Bulgaria | 4000 | |
20 | MHAT Central Onco Hospital | Plovdiv | Bulgaria | 4002 | |
21 | Acibadem City Clinic Multiprofile Hospital for Active Treatm | Sofia | Bulgaria | 1407 | |
22 | UMHAT Alexandrovska EAD | Sofia | Bulgaria | 1431 | |
23 | UMHAT Prof. Dr Aleksandar Chirkov | Sofia | Bulgaria | 1431 | |
24 | University Multiprofile Hosp. for Active Treat. Sveti Ivan | Sofia | Bulgaria | 1431 | |
25 | UMHAT Tsaritsa Yoanna-ISUL Clinic of imaging diagnostic | Sofia | Bulgaria | 1527 | |
26 | St.Joseph's Health Care-London | London | Ontario | Canada | N6G 2M3 |
27 | Toronto General Hospital UHN | Toronto | Ontario | Canada | M5G 2C4 |
28 | Hopital du Sacre-Coeur de Montreal | Montreal | Quebec | Canada | QC H4J 1C5 |
29 | London Health Sciences Centre (LHSC) - University Hospital | London | Canada | N6A 5A5 | |
30 | Nanfang Hospital, Southern Medical University | Guangzhou | Guangdong | China | 510515 |
31 | The First Affiliated Hospital of Jinan University | Guangzhou | Guangdong | China | 510630 |
32 | Huai'an First People's Hospital, Nanjing Medical University | Huai'An | Jiangsu | China | 223300 |
33 | Zhongda Hospital Southeast University | Nanjing | Jiangsu | China | 210009 |
34 | West China Hospital Sichuan University | Chengdu | Sichuan | China | 610041 |
35 | The First Affiliated Hospital of Wenzhou Medical University | Wenzhou | Zhejiang | China | 325000 |
36 | Beijing Chaoyang Hospital, Capital Medical University | Beijing | China | 100020 | |
37 | Peking University First Hospital | Beijing | China | 100034 | |
38 | Beijing Hospital | Beijing | China | 100730 | |
39 | Fakultni nemocnice Brno | Brno | Czechia | 625 00 | |
40 | Fakultni nemocnice Ostrava | Ostrava | Czechia | 708 52 | |
41 | Nemocnice Pardubickeho kraje, a.s., Pardubicka nemocnice | Pardubice | Czechia | 530 03 | |
42 | Fakultni nemocnice Plzen - Lochotin | Plzen | Czechia | 32300 | |
43 | Fakultni Thomayerova Nemocnice | Prague | Czechia | 140 59 | |
44 | Vseobecna fakultni nemocnice v Praze | Praha 2 | Czechia | 12808 | |
45 | Centre Hospitalier Universitaire - Angers | Angers | France | 49100 | |
46 | Hôpital Général - Dijon | Dijon | France | 21033 | |
47 | Hospices Civils de LYON | Lyon | France | 69229 | |
48 | Hopital Bichat - Paris | Paris | France | 75018 | |
49 | Uniklinik Freiburg / Radiologie | Freiburg | Baden-Württemberg | Germany | 79106 |
50 | Universitätsmed Göttingen Institut f. Diag&Interv Radiologie | Göttingen | Niedersachsen | Germany | 37075 |
51 | Uniklinik Bonn / Radiologie | Bonn | Nordrhein-Westfalen | Germany | 53127 |
52 | Helios Herzzentrum Leipzig - Abteilung für Radiologie | Leipzig | Sachsen | Germany | 04289 |
53 | Universitätsklinikum Aachen / Klinik für Diagnostische und Interventionelle Radiologie | Aachen | Germany | 52074 | |
54 | HELIOS Klinikum Berlin - Buch | Berlin | Germany | 13125 | |
55 | Universitätsklinikum Essen - Institut für Diagnostische und Interventionelle Radiologie und Neuroradiologie - 21197 | Essen | Germany | 45147 | |
56 | Debreceni Egyetem Klinikai Kozpont | Debrecen | Hungary | 4032 | |
57 | Flor Ferenc Korhaz | Kistarcsa | Hungary | 2143 | |
58 | BAZMKK es EOK, Kozponti Diagnosztikai Centrum | Miskolc | Hungary | 3526 | |
59 | Pecsi Tudomanyegyetem Klinikai Kozpont | Pecs | Hungary | 7623 | |
60 | Trial Pharma Kft. Szeged | Szeged | Hungary | 6726 | |
61 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Roma | Lazio | Italy | 00168 |
62 | A.O.U. Sant'Andrea | Roma | Lazio | Italy | 00189 |
63 | ASST Spedali Civili di Brescia | Brescia | Lombardia | Italy | 25123 |
64 | Ospedale San Raffaele s.r.l. | Milano | Lombardia | Italy | 20132 |
65 | ULSS2 Marca Trevigiana | Treviso | Veneto | Italy | 31100 |
66 | Nagoya Tokushukai Genaral Hospital | Kasugai | Aichi | Japan | 487-0016 |
67 | JCHO Kyushu Hospital | Kitakyushu | Fukuoka | Japan | 806-8501 |
68 | Hospital of the University of Occupational and Environmental Health, Japan | Kitakyushu | Fukuoka | Japan | 807-8556 |
69 | Hokkaido University Hospital | Sapporo | Hokkaido | Japan | 060-8648 |
70 | Hyogo Prefectural Nishinomiya Hospital | Nishinomiya | Hyogo | Japan | 662-0918 |
71 | Public Central Hospital of Matto Ishikawa | Hakusan | Ishikawa | Japan | 924-8588 |
72 | National Hospital Organization Kanazawa Medical Center | Kanazawa | Ishikawa | Japan | 920-8650 |
73 | Takamatsu Red Cross Hospital | Takamatsu | Kagawa | Japan | 760-0017 |
74 | Kishiwada Tokushukai Hospital | Kishiwada | Osaka | Japan | 596-0042 |
75 | Japan Organization of Occupational Health and Safety Sanin Rosai Hospital | Yonago | Tottori | Japan | 683-8605 |
76 | National Hospital Organization Kanmon Medical Center | Shimonoseki | Yamaguchi | Japan | 752-8510 |
77 | Social Medical Corporation the Chiyukai foundation Fukuoka Wajiro Hospital | Fukuoka | Japan | 811-0213 | |
78 | Hakodate Central General Hospital | Hakodate | Japan | 040-8585 | |
79 | Hanyu General Hospital | Hanyu | Japan | 348-8505 | |
80 | Osaka City General Hospital | Osaka | Japan | 534-0021 | |
81 | Ajou University Hospital | Suwon | Gyeonggido | Korea, Republic of | 443-721 |
82 | Seoul National University Hospital | Seoul | Seoul Teugbyeolsi | Korea, Republic of | 03080 |
83 | Konkuk University Medical Center | Seoul | Seoul Teugbyeolsi | Korea, Republic of | 05030 |
84 | Asan Medical Center | Seoul | Seoul Teugbyeolsi | Korea, Republic of | 05505 |
85 | NZOZ Kendron | Bialystok | Poland | 15-402 | |
86 | Uniwersyteckie Centrum Kliniczne | Gdansk | Poland | 80-214 | |
87 | Centra Medyczne Medyceusz | Lodz | Poland | 91-053 | |
88 | Centrum Medyczne HCP Sp. z o.o. | Poznan | Poland | 61-485 | |
89 | Centrum Medycznym Gamma | Warszawa | Poland | 01-785 | |
90 | Karolinska University Hospital Huddinge Radiology | Stockholm | Sweden | 14186 | |
91 | Akademiska Sjukhuset | Uppsala | Sweden | 751 85 | |
92 | Taipei Medical University - Shuang Ho Hospital | New Taipei City | Taiwan | 23561 | |
93 | Taichung Veterans General Hospital | Taichung | Taiwan | 40705 | |
94 | Chi Mei Medical Center - Medical Imaging Department | Tainan | Taiwan | 71004 | |
95 | Taipei Medical University Hospital - Medical Imaging department | Taipei | Taiwan | 110 | |
96 | Taipei Municipal Wanfang Hospital | Taipei | Taiwan | 116 | |
97 | Tri-Service General Hospital | Taipei | Taiwan | ||
98 | Lokman Hekim Universitesi Tip Fakultesi - Radyoloji | Ankara | Turkey | 06510 | |
99 | Binali Yildirim Universitesi Mengucek Gazi EAH - Radyoloji | Erzincan | Turkey | 24610 | |
100 | Koc Universitesi Tip Fakultesi - Radyoloji | Istanbul | Turkey | 34010 | |
101 | Istanbul Universitesi Istanbul Tip Fakultesi | Istanbul | Turkey | 34093 | |
102 | Istanbul Universitesi Cerrahpasa-Cerrahpasa Tip Fakultesi | Istanbul | Turkey | 34098 | |
103 | Ondokuz Mayis Uni Tip Fakultesi | Samsun | Turkey | 55139 | |
104 | Queen Elizabeth University Hospital | Glasgow | Glasgow City | United Kingdom | G51 4TF |
105 | University Hospital of Wales | Cardiff | United Kingdom | CF14 4XW | |
106 | Royal Infirmary of Edinburgh | Edinburgh | United Kingdom | EH16 4SA | |
107 | Nottingham University Hospital | Nottingham | United Kingdom | NG7 2UH |
Sponsors and Collaborators
- Bayer
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 21197
- 2022-501885-24-00